To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

2019 Alzheimer's Disease-Related Dementia (ADRD) Summit

The National Institutes of Health (NIH) is convening the 3rd Alzheimer's Disease-Related Dementia Summit, to be held on March 14-15, 2019 in Bethesda, Maryland. The 2019 Summit will bring together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and NIH to discuss progress made on dementia related research and develop recommendations that will help facilitate new scientific discoveries.

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

2018 Alzheimer’s Disease Research Summit

National Institutes of Health convened the 3rd Alzheimer’s Disease (AD) Research Summit on March 1-2, 2018 in Bethesda, Maryland. The program built on the foundation laid by the 2012 and 2015 NIH AD Research Summits and the U.S. National Alzheimer’s Project Act (NAPA)/National Plan to Address AD.

National Research Summit on Dementia Care: Building Evidence for Services and Supports

On October 16-17, 2017, the National Advisory Council on Alzheimer’s Research, Care and Services held a two-day Summit on the NIH campus entitled: National Research Summit on Dementia Care: Building Evidence for Services and Supports. The purpose of the Summit was to address the growing need for evidence that improves the quality of care and support provided to persons with dementia and their caregivers.

Cognitive Aging Summit III

Cognitive Aging Summit III will bring together experts in a variety of research fields to discuss the most cutting edge advances in our understanding of age-related brain and cognitive changes, with a particular focus on resilience and reserve.

International Summit in Human Genetics and Genomics

The International Summit in Human Genetics and Genomics is a five-year initiative (2016-2020) designed to help developing nations build and expand their knowledge base, infrastructure, systems and technologies in genetics and genomics. Each fall, researchers from abroad travel to the National Institutes of Health in Bethesda, Maryland for one month of in-person training at the National Human Genome Research Institute (NHGRI). The Summit helps them to understand the prevalence and basis of genetic diseases in their nations and to address these public health challenges. The 2019 Summit will be held on August 28 - September 28, 2019.

2016 Alzheimer's Disease-Related Dementias (ADRD) Summit

The 2016 Alzheimer’s Disease-Related Dementias (ADRD) Summit was hosted by the National Institute of Neurological Disorders and Stroke (NINDS) in collaboration with the National Institute on Aging (NIA) and held March 29-30, 2016 at the Natcher Auditorium on the NIH Campus.

Accelerating Medicines Partnership - Alzheimer's Disease

The Accelerating Medicines Partnership Alzheimer’s Disease Project (AMP-AD) is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. 

Biomarkers Consortium - Inflammatory Markers for Early Detection and Subtyping of Neurodegenerative and Mood Disorders

This project will aim to standardize and validate measurement methods for inflammatory markers associated with Alzheimer’s Disease and/or Major Depressive Disorder to ultimately identify a unique biosignature of disease. The identified biosignature would greatly assist with medication development, patient diagnosing, and patient selection for clinical trials.

Biomarkers Consortium - Use of Targeted Multiplex Proteomic Strategies to Identify CSF-Based Biomarkers in Alzheimer’s Disease

The AD Targeted Cerebrospinal Fluid (CSF) Proteomics Project, completed in Q2Y15, completed an initial validation of a multiplexed panel of known biomarkers, examined BACE levels and enzymatic activity, and set up the initial validation of a mass spectroscopy panel using AD cerebrospinal fluid samples from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).